Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 11 Ganglioneuroblastoma 3 Osteosarcoma 1 Neoplasm, Residual 1 Leiomyosarcoma 1

Interventions

Gemcitabine 13 Doxorubicin 8 Docetaxel 7 Trabectedin 5 pazopanib 4 Nivolumab 4 Temozolomide 3 Specimen Handling 3 Sorafenib 3 rucaparib 2 pembrolizumab 2 liposomal doxorubicin 2 durvalumab 2 brostallicin 2 Sunitinib 2 Radiotherapy 2 Radiation Dose Hypofractionation 2 Magnetic Resonance Spectroscopy 2 Letrozole 2 Ifosfamide 2 Dacarbazine 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 saracatinib 1 rubitecan 1 romidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leiomyosarcoma × dinutuximab × Clear all

NCT05080790 2025-08-17

DiTuSarc

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡